MUSC Hollings Cancer Center - Report to the Community 2026 - Flipbook - Page 8
Cancer Discoveries
Discovery exposes
an Achilles’ heel in
kidney cancer
A
common genetic mutation that helps some
kidney cancers survive may also create an
unexpected weakness that MUSC Hollings
Cancer Center researchers hope to turn into a new
treatment strategy.
The team also uncovered the biology behind that
vulnerability. Loss of SETD2 caused mitochondrial DNA
to leak into the cell, triggering an in昀氀ammatory response
similar to a viral infection. Blocking BCL-xL intensi昀椀ed
that response, pushing cancer cells toward death and
making them more visible to the immune system. The
discovery points to mitochondrial DNA leakage as an
unrecognized driver of immune activity in kidney cancer.
The 昀椀ndings reveal both new insights into the biology of
kidney cancer and a potential therapeutic opportunity. A
new 昀椀ve-year National Cancer Institute grant will allow de
Cubas to build on the discovery, investigating whether
combining BCL-xL inhibition with immunotherapy could
produce a stronger anti-tumor response.
A study led by Aguirre de Cubas, Ph.D., found that
kidney cancer cells lacking the tumor suppressor
gene SETD2 become highly dependent on another
protein, called BCL-xL, for survival. When researchers
blocked BCL-xL in laboratory models, SETD2-de昀椀cient
cancer cells died rapidly while cells with intact SETD2
were largely unaffected – revealing a potential way to
selectively target an aggressive subset of kidney cancers.
RESEARCH PROGRAMS
SELECT
HIGH-IMPACT
PUBLICATIONS
6 | MUSC Hollings Cancer Center
Cancer Biology & Immunology
Cancer Prevention & Control
Developmental Cancer Therapeutics